Cardiopulmonary exercise testing of a patient with chronic thromboembolic pulmonary hypertension showing fields 4, 6 and 9 of the Wasserman panel. a) Elevated.

Slides:

Advertisements

Similar presentations

PaCO2 equation Alveolar Ventilation 1.

Advertisements

Chart 1: Oxygen prescription for acutely hypoxaemic patients in hospital. Chart 1: Oxygen prescription for acutely hypoxaemic patients in hospital. ABG,

Recommended algorithm for high-flow nasal cannula use in acute hypoxaemic respiratory failure in immunocompetent or immunocompromised patients. #: arterial.

A 45-year-old with pulmonary hypertension

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).

Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018 Heinrike Wilkens, Stavros Konstantinides,

Example of a volumetric capnogram.

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.

Algorithm for the diagnosis and treatment of hepatopulmonary syndrome (HPS). Algorithm for the diagnosis and treatment of hepatopulmonary syndrome (HPS).

Schematic diagram of the potential psychophysiological mechanism of perception of breathlessness in obese adults with dyspnoea on exertion. 1: increased.

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

A–f) Respiratory mechanical measurements during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease (COPD) and age-matched.

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Difference of oxygen uptake efficiency (OUE; oxygen uptake (V′O2)/minute ventilation (V′E)) plateau between a typical pulmonary arterial hypertension (PAH)

Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.

Arterial oxygen saturation (SaO2) patterns during sleep in obstructive sleep apnoea (OSA) alone and the overlap syndrome. Arterial oxygen saturation (SaO2)

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Effects of chronic obstructive pulmonary disease (COPD) severity on different parameters of ventilatory inefficiency during incremental cardiopulmonary.

Effect of intravenous furosemide in a pulmonary arterial hypertension patient admitted with overt right heart failure documented by echo-Doppler of the.

Mean change from baseline in 6-min walking distance (6MWD) in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial.

Algorithm for the assessment of fitness to fly in chronic obstructive pulmonary disease patients. Algorithm for the assessment of fitness to fly in chronic.

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

Right ventricular (RV) pressure–volume loops at decreasing venous return in a patient with a) systemic sclerosis-associated pulmonary arterial hypertension.

Model for the association between pathological features, physiological alterations and their association with pathological and clinical features. Model.

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

Exertional dyspnoea intensity is shown relative to a) work rate and b) diaphragm electromyography relative to maximum (EMGdi/EMGdi,max) during incremental.

Pulmonary angiography in the right lung (a, c, e and g) and the left lung (b, d, f and h) of a patient with chronic thromboembolic pulmonary hypertension.

The minute ventilation (V′E)/carbon dioxide production (V′CO2) relationship slope in a patient with pulmonary arterial hypertension and preserved physiological.

Oxygen uptake and carbon dioxide removal in the membrane lung

A 50-year-old male with persistent abnormality on computed tomography (CT) despite anticoagulation for 1 year. a) CT scan showing an expansile low attenuation.

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Management of patients with obesity hypoventilation syndrome (OHS) from diagnosis to integrated care to modify health trajectories. Management of patients.

Distribution of mutations in sporadic and familial pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary.

Change in physiological variables from baseline values a) at rest and b) during exercise after saline infusion and exposition to different β-blocker agents.

Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.

Definition of pulmonary hypertension (PH) associated with left heart disease. mPAP: mean pulmonary arterial pressure; PAWP: pulmonary artery wedge pressure;

Laplace's law: T = (P×r)/2h.

A) Conventional pulmonary angiogram, with b) and c) corresponding optical coherence tomography images from a patient with chronic thromboembolic pulmonary.

Kaplan–Meier plots for a) clinical worsening and b) survival in the overall population during the Chronic Thromboembolic Pulmonary Hypertension Soluble.

Example scans for a typical patient with operable chronic thromboembolic pulmonary hypertension. a) Perfusion (Q′) and b) ventilation (V′) lung scans.

Mean pulmonary arterial pressure (Ppa) as a function of cardiac output (Q) at two different levels of pulmonary vascular resistance (PVR). Mean pulmonary.

Effect of pulmonary arterial hypertension (PAH) on SF-36-measured health-related quality of life (HRQoL) measures versus the normal population and other.

Changes in inspired oxygen tension (PiO2), Alveolar-arterial oxygen gradient (A-a DO2), arterial oxygen tension (PaO2), and carbon dioxide tension (PaCO2)

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Marco Guazzi et al. JACC 2017;70:

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Examples of ventilatory efficiency slope (minute ventilation (V′E)/carbon dioxide production (V′CO2) slope) in a healthy subject (green line) and a patient.

Effect of pulmonary arterial hypertension-specific treatment on systemic inflammation. a) Kaplan–Meyer survival curves for patients normalising their C-reactive.

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

Diagnostic algorithm for chronic thromboembolic pulmonary hypertension

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Patient with inoperable chronic thromboembolic pulmonary hypertension showing a typical aspect of subpleural hypoperfusion at the capillary phase of pulmonary.

Distribution and change of the underlying disease in patients discharged with home mechanical ventilation (n = 854). ♦: chronic obstructive pulmonary disease;

A) Operating lung volumes and b) breathing frequency (Fb) during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

A 53-year-old patient with fibrosing mediastinitis

A–f) Diaphragm electromyography (EMGdi) and selected ventilatory and indirect gas exchange responses to incremental cycle exercise test in patients with.

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Treatment algorithm for chronic thromboembolic pulmonary hypertension.

Simulation of a patient with a constant shunt of 20% of the cardiac output who is breathing 100% O2. a) Arterial partial pressure of oxygen (PO2) is very.

Real-life pulmonary arterial hypertension (PAH) patient cases to reflect the importance of a collaborative approach to patient engagement. Real-life pulmonary.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Cardiopulmonary exercise testing of a patient with chronic thromboembolic pulmonary hypertension showing fields 4, 6 and 9 of the Wasserman panel. a) Elevated slope of minute ventilation (V′E)/carbon dioxide output (V′CO2) ratio showing hyperventilation (fi... Cardiopulmonary exercise testing of a patient with chronic thromboembolic pulmonary hypertension showing fields 4, 6 and 9 of the Wasserman panel. a) Elevated slope of minute ventilation (V′E)/carbon dioxide output (V′CO2) ratio showing hyperventilation (field 4); b) elevated ventilator equivalents for oxygen (EQO2) and carbon dioxide (EQCO2) showing ineffective ventilation (field 6); c) low and decreasing end-tidal carbon dioxide tension (PETCO2), elevated alveolar–arterial oxygen tension gradient (PA–aO2) and elevated arterial–end-tidal carbon dioxide gradient (Pa–ETCO2) (field 9). PETO2: end-tidal oxygen tension; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; PO2: oxygen tension; PCO2: carbon dioxide tension. Deepa Gopalan et al. Eur Respir Rev 2017;26:160108 ©2017 by European Respiratory Society